Gene Therapy Casgevy denied as non-formulary by Humana?

Humana's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Casgevy as Non-Formulary

Because Casgevy is a gene therapy administered once in a specialized center — not a recurring prescription — most commercial formularies do not carry it as a standard covered line item. Humana's non-formulary denial means the drug is not on your plan's approved drug list, but this does not mean coverage is impossible. Federal law and Humana's own appeals process provide a structured path to obtain a formulary exception.

## Why This Denial Is Appealable

Plans subject to the ACA must cover drugs when a formulary exception is medically warranted and no formulary alternative is clinically appropriate. For ERISA-governed employer plans, §503 requires a full-and-fair review of any adverse benefit determination. Because there is no formulary equivalent to a curative gene therapy, the exception argument is especially strong.

## Federal Appeal Framework

• Formulary exception request / internal appeal: Submit simultaneously or in sequence depending on your plan documents. Request the specific form or process Humana uses for formulary exceptions.
• External review: If denied after internal appeal, you have approximately four months from the final denial to request IRO review under ACA §2719 or applicable state law.
• Expedited track: Available when delay would jeopardize health or ability to complete a treatment protocol with timing requirements.

## Documentation to Gather

1. No adequate formulary alternative: A letter from your hematologist explaining that no covered formulary drug provides an equivalent benefit for your specific condition and clinical situation. 2. Diagnosis and severity records: Chart documentation confirming diagnosis and the degree of disease burden that makes a curative approach medically appropriate. 3. Prior treatments: Records showing the course of prior therapies, including dates, doses (obtained from those records), and outcomes. 4. FDA prescribing label: Reference the approved indication in the label to show this is an on-label use. 5. Specialist opinion: A detailed medical-necessity letter from your treating hematologist, referencing applicable ASH or other relevant society guidelines generically.

## Criteria-Mapping Strategy

Obtain Humana's formulary exception criteria from your plan documents or by calling member services. Map each requirement to a specific document in your record. The core argument is: (1) Casgevy is FDA-approved for your exact diagnosis; (2) no formulary drug is therapeutically equivalent; and (3) your clinical profile meets the evidence-based criteria in the prescribing label and relevant professional guidelines. Present this as a numbered point-by-point response to each denial reason Humana cited.